주식/증권
📈 긍정적
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
요약
Gilead's expansion beyond HIV therapies will surprise many investors.